Zai Lab Limited (HKG:9688)
21.48
+0.52 (2.48%)
Nov 10, 2026, 4:08 PM HKT
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or 4.55% compared to the previous year. That makes Zai Lab the 10,982nd largest employer in the world and 814th in Hong Kong.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
1.94M HKD
Profits / Employee
-872.60K HKD
Market Cap
23.68B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 1,784 | -85 | -4.55% | 1,784 | 0 |
| Dec 31, 2024 | 1,869 | -306 | -14.07% | 1,869 | 0 |
| Dec 31, 2023 | 2,175 | 139 | 6.83% | 2,175 | 0 |
| Dec 31, 2022 | 2,036 | 85 | 4.36% | 2,036 | 0 |
| Dec 31, 2021 | 1,951 | 757 | 63.40% | 1,951 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| 3SBio | 6,068 |
| Shanghai Henlius Biotech | 4,082 |
| Shanghai Junshi Biosciences | 3,055 |
| Biocytogen Pharmaceuticals (Beijing) | 1,922 |
| Keymed Biosciences | 1,768 |
| InnoCare Pharma | 1,388 |
| Ascentage Pharma Group International | 828 |
| Everest Medicines | 812 |
Zai Lab News
- 20 hours ago - Consensus Price Target for Zai Lab Limited - Depositary Receipt Increased by 12.10% to $31.30 - Nasdaq
- 3 days ago - Zai Lab Q3 Earnings Call Highlights - MarketBeat
- 4 days ago - Zai Lab (ZLAB) Q3 2026 Earnings Call Transcript - The Motley Fool
- 4 days ago - Zai Lab presents updated clinical data on zocilurtatug pelitecan - TheFly
- 4 days ago - Zai Lab Presents Updated Clinical Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Clinically Meaningful Responses and a Manageable Safety Profile in Previously Treated Extrapulmonary Neuroendocrine Carcinomas - Business Wire
- 4 days ago - Zai Lab Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Zai Lab Earnings release: Q3 2026 - Filings
- 4 days ago - Zai Lab Quarterly report: Q3 2026 - Filings